
Long Non-Coding Rna Signatures to Classify Multiple SclerosisAward last edited on: 9/21/2022
Sponsored Program
SBIRAwarding Agency
NIH : NIAIDTotal Award Amount
$1,480,278Award Phase
2Solicitation Topic Code
855Principal Investigator
Charles Floyd SpurlockCompany Information
IQuity Labs Inc (AKA: IQuity Inc)
4015 Hillsboro Pike Suite 214
Nashville, TN 37215
Nashville, TN 37215
(855) 899-9551 |
info@iquitylabs.com |
www.iquitylabs.com |
Location: Single
Congr. District: 05
County: Davidson
Congr. District: 05
County: Davidson
Phase I
Contract Number: 1R43AI124766-01Start Date: 3/1/2016 Completed: 2/28/2017
Phase I year
2016Phase I Amount
$159,825Public Health Relevance Statement:
Public Health Relevance:
Diagnosis of autoimmune diseases, including multiple sclerosis (MS), can be a difficult, long and costly process and mis-diagnosis of MS is not uncommon. Long non-coding RNAs (lncRNA) are a new class of regulatory RNA molecules that exhibit high degrees of cell-type specific expression. The hypothesis we will test in this application is that measurement of expression of disease-specific lncRNAs in MS will have greater utility to provide meaningful clinical information to health-care providers than faced with these diagnostic dilemmas than measurement of disease-specific mRNAs.
Project Terms:
Address; Autoimmune Diseases; base; Biological Markers; Biological Process; Categories; cell type; Cerebrospinal Fluid; Clinical; Code; Complex; cost; Data; Demyelinations; Detection; Diagnosis; Diagnostic; Diagnostic tests; differential expression; Disease; Event; Evoked Potentials; Exhibits; experience; Fibromyalgia; Gene Expression Profile; Genes; Health Personnel; Healthcare; Healthcare Systems; Hour; Human; human disease; infancy; Inflammation; Invertebrates; Irritable Bowel Syndrome; Laboratories; Magnetic Resonance Imaging; Measurement; Messenger RNA; Multiple Sclerosis; nervous system disorder; Neurologic; novel; Oligoclonal Bands; Organism; Pattern; Persons; Process; Proteins; public health relevance; Research; Research Subjects; Rest; RNA; Symptoms; Syndrome; Systemic Scleroderma; Testing; Time; United States; Untranslated RNA; Vertebrates; Whole Blood
Phase II
Contract Number: 2R44AI124766-02A1Start Date: 3/1/2016 Completed: 5/31/2019
Phase II year
2017(last award dollars: 2018)
Phase II Amount
$1,320,453Public Health Relevance Statement:
Diagnosis of relapsing remitting multiple sclerosis (MS) is a subjective diagnosis based largely on clinical symptoms and MRI findings disseminated in time and space. Biomarkers to aid and accelerate this diagnosis is an area of active investigation. Long non-coding RNAs (lncRNAs) are newly discovered classes of RNAs with an array of regulatory functions. Our hypothesis to test, and supported by our phase 1 studies, is that classifiers can be built based upon differential expression of lncRNAs in blood. These classifiers will possess greater accuracy to identify presence of MS in a subject earlier than is currently available leading to preservation of brain health.
Project Terms:
Address; Adopted; Advocate; American; Area; Asians; Autoimmune Diseases; base; Biological Markers; Biological Preservation; Biological Process; Blood; Brain; brain health; Categories; cell type; Clinical; Code; cohort; Complex; cost; Data; Demyelinations; Diagnosis; Diagnostic tests; differential expression; Disease; disorder control; Early Diagnosis; Early Intervention; Europe; European; Event; Exhibits; experience; Face; Fibromyalgia; Foundations; Gene Expression Profile; Genes; Geographic Distribution; health organization; Healthcare; Healthcare Systems; Hour; Human; human disease; infancy; Inflammation; Inflammatory; International; Invertebrates; Investigation; Irritable Bowel Syndrome; Laboratories; Latin American; Machine Learning; Magnetic Resonance Imaging; Messenger RNA; Middle East; Multiple Sclerosis; nervous system disorder; neuroimmunology; Neurologic; Neurologist; Northern Africa; Nurses; Organism; Paper; Patients; Pattern; Peripheral; Persons; Phase; phase 1 study; Positioning Attribute; Proteins; Provider; Relapsing-Remitting Multiple Sclerosis; Research; Research Subjects; Rest; RNA; Site; Societies; Spinal Cord; Suggestion; Symptoms; Syndrome; Systemic Scleroderma; Testing; Therapeutic; Time; Tissues; Trust; United States; Untranslated RNA; Vertebrates; Whole Blood; Work